Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee of the French Association of Urology.

Stéphanie DelavalPierre-Luc DequirezClaire HentzenMaximilien BaronEva MilleFrançois TarielBenoit PeyronnetMarie-Aimée Perrouin-VerbeAdeline PieracheEmmanuel Chartier-KastlerGrégoire CaponJean-Nicolas CornuEvelyne Castel-LacanalXavier GaméGilles KarsentyAlain RuffionPierre DenysAlexia EvenCharles JoussainGérard AmarencoVéronique PhéXavier Biardeau

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)

BoNT-A is a satisfying mid-term neurogenic OAB/DO therapy for most MS patients. Combining EDSS and MS type could help predict BoNT-A discontinuation.

Keyphrases

multiple sclerosis
end stage renal disease
mass spectrometry
ejection fraction
ms ms
chronic kidney disease
newly diagnosed
prognostic factors
spinal cord injury
urinary tract
white matter
muscle invasive bladder cancer
patient reported